CTOs on the Move

Medefil Inc

www.medefil.com

 
Medefil Inc is a Glendale Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medefil.com
  • 250 Windy Point Dr
    Glendale Heights, IL USA 60139
  • Phone: 630.682.4600

Executives

Name Title Contact Details

Similar Companies

Nutravail Technologies

Nutravail Technologies is a Chantilly, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anji Pharmaceuticals

Anji Pharma is a global pharmaceutical company focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

Acerta Pharma B.V.

Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer.

WellSpring Pharmaceutical Corporation

WellSpring Pharmaceutical Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.